Introduction {#s0002}
============

Gram-negative, non-fermenting bacteria are an emerging concern in clinical locations, being a common cause of nosocomial infections. Opportunistic pathogens from this group include many different bacterial species, including: *Acinetobacter baumannii*, *Burkholderia cepacia*, *Ralstonia pickettii*, *Pseudomonas aeruginosa*, *Sphingomonas pauciomobilis*, and *Stenotrophomonas maltophilia* \[[@cit0001]\]. The group can survive in a wide variety of environments including different water sources (aircraft water, bottled water, hospital water, purified water) \[[@cit0009]\], and are usually resistant to a wide array of antimicrobials \[[@cit0013],[@cit0014]\]. Examples include resistance to penicillins, aminoglycosides and monobactems in *R. pickettii* \[[@cit0013]\] and penicillins, aminoglycosides, carbapenems and monobactems in *S. maltophilia* \[[@cit0014]\]. Bacteria such as these have the ability to infect patients/individuals with underlying medical conditions and diseases. Examination of the scientific literature showed multiple types of infections resulting from *Brevundimonas* spp. This indicates that the genus may be a more widespread pathogen than was hitherto thought, with infections caused by *Brevundimonas* spp. being invasive and severe. The goal of this study was to give an overview of the range of *Brevundimonas* spp infections, any underlying conditions associated with *Brevundimonas* spp infections and the treatment options used in the treatment of any *Brevundimonas* spp infections in order to assist medical practitioners.

Genus Brevundimonas {#s0002-0001}
-------------------

The genus *Brevundimonas* was first proposed by Segers et al \[[@cit0015]\]; incorporating *Pseudomonas diminuta* and *Pseudomonas vesicularis* \[[@cit0016],[@cit0017]\]. Several species of the genus *Caulobacter* were later transferred to *Brevundimonas* significantly emending the description of the genus \[[@cit0018]\]. Currently, there are 25 species with valid published names within the *Brevundimonas* genus (<http://www.bacterio.net/brevundimonas.html>). The type species is *Brevundimonas diminuta*; with the type strain being LMG 2089.

*Brevundimonas* species are aerobic Gram-negative, oxidase and catalase positive, non-fermenting rods 1 to 4 μm in length and 0.5 μm in width, belonging to the Alphaproteobacteria class and Caulobacteraceae family with a DNA G + C content of 65% to 68% \[[@cit0015]\]. Motility is provided by one short polar flagellum. *Brevundimonas* spp. have been isolated from multiple environments, including soils \[[@cit0009]\], deep subsea floor sediment \[[@cit0022]\] activated sludge,\[[@cit0023]\] black sand, \[[@cit0024]\], deep subsea floor sediment \[[@cit0025]\] numerous aquatic habitats \[[@cit0026]\], purified water \[[@cit0027]\] and also from the condensation water of a Russian space laboratory \[[@cit0028]\].

Brevundimonas spp. {#s0003}
==================

Brevundimonas diminuta {#s0003-0001}
----------------------

*Brevundimonas diminuta* is the type species of the *Brevundimonas* genus. It has been isolated from clinical specimens, including blood and urine \[[@cit0015]\] as well as from the lung sputum of cystic fibrosis patients \[[@cit0029]\]. *B. diminuta* is not believed to be a significant pathogen and its virulence is generally low. *B. diminuta* is used as a test organism to validate reverse-osmosis (RO) filtration devices for drinking water purification and is also used to test the porosity of pharmaceutical-grade filters (0.2 μm) due to the small size of the bacterium when grown in minimal media \[[@cit0030],[@cit0031]\]. The bacterium has however been shown to be capable of penetrating these filters \[[@cit0032]\]. The bacterium has been used as a potential bioremediator of marine oil pollution including diesels, n-alkanes and polycyclic aromatic hydrocarbons \[[@cit0033],[@cit0034]\] and insecticides \[[@cit0035]\]. *B. diminuta* has also been used to mitigate the toxic effects of heavy metals on plant growth (rice) in contaminated soils \[[@cit0036]\]. *B. diminuta* also possesses the ability to survive sanitizers such as Hydrogen Peroxide + Peracetic Acid \[[@cit0037]\]. All available reported incidences of infection credited to *B. diminuta* are listed in [Table 1](#t0001){ref-type="table"}-[3](#t0003){ref-type="table"}. Table 1.Incidences of *Brevundimonas* spp. infection from 1978--2000 -- Main characteristics of the case reports.Author (Ref)/ SpeciesYearSex/AgeCountryCo-morbidityType of infectionSusceptible toResistance toAntibiotic treatmentOutcomeOtto et al. \[[@cit0053]\], *B. vesicularis*1978Multiple cases (5 cases)USAN/ACervicitisAmpicillin, Carbenicillin, Gentamicin, Kanamycin Nitrofurantoin, Streptomycin, TetracyclineColistin, Nalidixic acid, SulfisoxazoleN/AN/AVanholder et al. \[[@cit0054]\], *B. vesicularis*1990M/62BelgiumHemodialysis,Bacteraemia/HAN/AN/ACefotaxime, TobramycinComplete recoveryVanholder et al. \[[@cit0055]\], *B. vesicularis*1992F/62BelgiumHemodialysis,Bacteraemia/HAN/AN/ACefotaxime, TobramycinComplete recoveryPlanes et al. \[[@cit0056]\], *B. vesicularis*1992W/54USASystemic lupus erythematosus and chronic active autoimmune hepatitisBacteraemia/HAN/AN/ACeftazidime, TobramycinSurgical resection of the infected tissuePasadakis et al. \[[@cit0057]\], *B. diminuta*1993N/AGreeceEnd-stage renal failurePeritonitisN/AN/AInitial 500 mg/L ceftazidime in a I-L + 1.7 mg/kg of tobramycin. Maintenance doses 250 mg/2 L of ceftazidime + 16 mg/2 L of tobramycinComplete recoveryOberhelman et al. \[[@cit0058]\], *B. vesicularis*1994M/5USASickle cell anaemiaPneumonia/CAN/AN/ACeftriaxone, GentamicinComplete recoveryCalegari et al. \[[@cit0059]\], *B. vesicularis*1996M/60UruguayTraumaBotryomycosis/CAN/AN/ACefuroximeComplete recoveryGilad et al. \[[@cit0060]\], *B. vesicularis*2000F/42IsraelMitral valve replacementBacteraemia/HAAmoxicillin-Clavulanate, Amino-glycosides, Co-trimoxazole, Imipenem, Mezlocillin, Piperacillin, Piperacillin- TazobactamAmpicillin, Aztreonam, Cefuroxime, Ceftriaxone, Ceftazidime, CiprofloxacinPiperacillin- TazobactamComplete recovery[^1]

Brevundimonas vesicularis {#s0003-0002}
-------------------------

*Brevundimonas vesicularis* has been isolated from eye, urine, wound cultures, the central nervous system, cervical specimens \[[@cit0038]\], and also been found in the lung sputum of cystic fibrosis patients \[[@cit0039]\]. The organism has been shown to support the growth of *Legionella* in nutrient limited water conditions \[[@cit0040]\]. The mechanism behind this phenomenon has not been elucidated but it is hypothesised to be due to cryptic growth, with *B. vesicularis* having the ability to grow in nutrient limited conditions and *Legionella* growing on this \[[@cit0040]\]. Further research is required to gain a fuller understanding of this phenomenon. *B. vesicularis* has been used as a potential bioremediator of polyaromatic hydrocarbons \[[@cit0041]\]. All reported incidences of infection credited to *B. vesicularis* are listed in [Table 1--3](#t0001 t0002 t0003){ref-type="table"}.

Identification of* Brevundimonas* spp {#s0003-0003}
-------------------------------------

Members of the *Brevundimonas* spp. are Gram negative with cells appearing as straight slim rods upon Gram staining. They are non-spore forming. They are aerobic with optimal growth temperatures of between 30--37°C. They are oxidase positive and give variable results for catalase (usually positive). *B. diminuta* colonies have a chalk white appearance on MacConkey agar, whereas *B. vesicularis* colonies have an orange colour given by an intracellular pigment. Both grow slowly on ordinary nutrient media \[[@cit0042]\]. Both *B. vesicularis* and *B. diminuta* can be identified via commercial biochemical identification kits or systems such as the API 20 NE system, the VITEK 2 system (bioMerieux) or the Phoenix-100 automated system (Becton Dickinson). MALDI-TOF identification is also being used for identification of *Brevundimonas* spp. in clinical situations \[[@cit0043],[@cit0044]\]. Species specific Real Time PCR primers and Fluorescence *in situ* hybridization (FISH) probes have been designed for *B. diminuta* \[[@cit0045]\]. These can be seen in [Table 4](#t0004){ref-type="table"}.

Factors associated with Infection {#s0004}
=================================

Underlying causes {#s0004-0001}
-----------------

The majority of infections with *Brevundimonas* ([Table 1--3](#t0001 t0002 t0003){ref-type="table"}) were found to have an underlying condition or disease that allowed patients to succumb to *Brevundimonas* infection. Seven patients, who were suffering with various types of cancer, contracted *Brevundimonas* -related bacteraemia, Urinary Tract Infection (UTI) and Empyema \[[@cit0046]\]; a 56-year-old female with *Lupus glomerulonephritis* acquired a *Brevundimonas* -related leg ulcer \[[@cit0047]\] and an infant suffering from Pompe disease was diagnosed with *Brevundimonas* -related bacteraemia \[[@cit0048]\]. Other examples of patients infected with *Brevundimonas* having underlying conditions are shown in [Table 1--3](#t0001 t0002 t0003){ref-type="table"}. Such examples demonstrate the role of *Brevundimonas* as an opportunistic pathogen in immunocompromised individuals. Many of these instances of infection were hospital acquired although a large number were community acquired, which is interesting as opportunistic pathogens such as *Brevundimonas* spp or *R. pickettii* are usually contracted in hospital settings \[[@cit0007]\]. Table 2.Incidences of *Brevundimonas* spp. infection from 2001 -- 2010. Main characteristics of the case reports.Author (Ref)YearSex/AgeCountryCo-morbidityType of infectionSusceptible toResistance toAntibiotic treatmentOutcomeLee et al. \[[@cit0061]\], Various2000--2010Multiple (30 cases)TaiwanCancer patientsBacteraemiaCiprofloxacin, Colistin, Doripenem, TigecyclineAmikacin, Piperacillin/tazobactamCefotaxime, Ceftazidime, Cefmetazole, Cefazolin, Cefuroxime, Ceftriaxone, Imipenem, Piperacillin/tazobactam, Ticaracillin-ClavulanateComplete recoverySeve et al. \[[@cit0062]\], *B. diminuta*2004F/35FranceLeukaemiaBacteraemia/HACiprofloxacin, ImipenemAmikacin, Cefepime and Ceftazidime, PiperacillinInitially Cefepime, Amikacin After susceptibility testing: Ciprofloxacin, ImipenemComplete recoveryChi et al. \[[@cit0063]\], *B. vesicularis*2004M/38TaiwanNoneTonsillitis/CACefoperazone.Ampicillin, Aztreonam, Cefazolin, Ceftazidime, Ciprofloxacin, Flomoxef, Gentamicin, TobramycinAmoxicillin/ Clavulanic acidComplete recoveryChi et al. \[[@cit0063]\], *B. diminuta*2004M/62TaiwanLiver cirrhosis, Encephalopathy, Spontaneous bacterial peritonitisBloodstream infection/CAAmikacin, Aztreonam, Cefotaxime, Cefepime, Chloramphenicol, Ciprofloxacin Flomoxef, Gentamicin, Imipenem, Piperacillin-Tazobactam, Tetracycline, Tobramycin, Co-trimoxazoleAmpicillin, Cefazolin, Cefoperazone, Ceftazidime, CeftriaxoneCefotaximeComplete recoveryHan et al., \[[@cit0046]\], *B. diminuta*2005Multiple (7 Cases)USACancerBacteraemia, Urinary Tract Infection, Empyema/HAAmikacin, Imipenem and Ticarcillin/clavulanateAmpicillin, Cefepime, CiprofloxacinCefepime, Imipenem, Levofloxacin, Meropenem, Nafcillin, Tobramycin, Ticarcillin/ clavulanate, VancomycinComplete recoveryKaradag et al. \[[@cit0038]\], *B. vesicularis*2005--2011Multiple (8 cases)TurkeyNeonatesSepticaemia/HAAmikacin, Imipenem,Aztreonam, Ceftazidime, Piperacillin/tazobactamAmpicillin, Cefotaxime, Ciprofloxacin, Meropenem,7 Complete recovery, 1 DiedVahid \[[@cit0064]\] *B. vesicularis*2005W/36USAAcute myelogenous leukaemiaBacteraemiaCiprofloxacin, Ticaracillin-ClavulanateAmikacin, Aztreonam, Cefepime, Ceftazidime, Ceftriaxone, Meropenem, Piperacillin/tazobactamInitially: Amikacin, Ampohotericin B, Gancyclovir VancomycinDiedPapaefstathiou et al., \[[@cit0065]\], *B. vesicularis*2005F/92GreeceCardiac failureBacteraemia/CAAmoxicillin-clavulanate, Aminoglycosides, Azlocillin, Aztreonam Second and Third-generation Cephalosporins, Imipenem, Piperacillin, Tetracycline, Trimethoprim-SulfamethoxazoleAmpicillin, Cephalothin, CiprofloxacinCefuroxime, NetilmicinDiedNiedermeier et al. \[[@cit0066]\], *B. vesicularis*2005F/37USAAcute myeloid leukemia, Pregnancy, PancytopeniaSepsis/HAN/AN/AClindamycin, Piperacillin-tazobactamComplete recovery from sepsisMondello et al. \[[@cit0067]\], *B. vesicularis*2006M/24ItalyPilocytic astrocytomaMeningitis/HACiprofloxacin, Co-trimoxazole, TetracyclineN/AInitially: Ceftriaxone, Ciprofloxacin, Co-trimoxazole After Treatment failure: AmikacinComplete recoveryChoi et al. \[[@cit0068]\], *B. vesicularis*2006M/55South KoreaDiabetes, Continuous ambulatory peritoneal dialysisPeritonitis/CAN/AN/AAztreonam, Cefazolin, Ceftazidime, Ciprofloxacin, VancomycinComplete recoveryYang et al. \[[@cit0069]\], *B. vesicularis*2006M/40TaiwanNoneEndocarditis/ CAAmikacin, Amoxicillin, Gentamicin, Piperacillin, Aztreonam, Cefepime, Meropenem, Netilmicin, Ampicillin, Ciprofloxacin, Cefazolin, Cefmetazole, Ceftazidime, Cefotaxime, Ceftriaxone, TicarcillinN/ACefazolin, GentamicinComplete recoveryZhang et al. \[[@cit0070]\], *B. vesicularis*2006--2009Multiple Cases (22 patients)TaiwanVarious (Cancer, heart failure, COPD, Kidney diease)Bacteraemia/CA/HAAmikacin, Cefpirome, Imipenem, Piperacillin/tazobactam,N/AVarious (Penicillin\'s, Cephalosporins)Complete recovery in 21 cases. 1 case of deathPelletier et al. \[[@cit0071]\], *B. vesicularis*2007F/45USANoneKeratitisCeftazidime, Ciprofloxacin, Gentamicin, LevofloxacinN/ACeftazidimeComplete recoverySofer et al., \[[@cit0072]\], *B. vesicularis*2007F/15 Month oldIsraelNoneSeptic Arthritis/CAAminoglycosides, Aminopenicillins, Cephalposporins, Piperacillin, Quinolones, Trimethoprim-sulfamethoxazoleN/ACefuroximeComplete recoveryMenuet et al. \[[@cit0029]\], *B. vesicularis*2008F/17FranceCystic FibrosisPneumoniaAmikacin, Ceftriaxone, Gentamicin, Imipenem, Isepamicin, Rifampicin, Piperacillin/tazobactam, Ticarcillin, Ticarcillin- Clavulanate, TobramycinAmoxicillin, Amoxicillin-Clavulanate, Ceftazidime, Ciprofloxacin, Colistin, Trimethoprim-SulfamethoxazoleImipenem, TobramycinComplete recoveryPanasiti et al. \[[@cit0073]\], *B. vesicularis*2008M/71ItalyNoneCutaneous Infection/CAAmikacin, Cefoxitin, Ceftazidime, Cefuroxime, Cefalotin, Cepodoxime, Gentamycin, TobramycinAmoxicillin-Clavulanate, Cefeoime, Ofloxacin, NorfloxacinAmoxicillin-ClavulanateComplete recoveryViswanathan et al. \[[@cit0074]\], *B. vesicularis*2009M/InfantIndiaNewbornSepsis/HAAmikacin, Cefotaxime, Ciprofloxacin, Gentamicin, Meropenem, Ofloxacin, Piperacillin tazobactamN/AAmikacin, CefotaximeComplete recoveryChandra et al. \[[@cit0075]\], *B. vesicularis*2010M/31USABiliary PancreatitisBacteraemiaAmikacin, Cefuroxime, Cefepime, Ciprofloxacin, Gentamicin, Piperacillin/tazobactam, Polymyxin B,Aztreonam.CefuroximeComplete recoveryRestrepo et al. \[[@cit0076]\], *B. vesicularis*2010F/44ColumbiaNone knownReactive Arthritis + BacteraemiaAmikacin, Imipenem, Meropenem, Piperacillin/tazobactamAztreonam, CiprofloxacinInitially: Amikacin, Ciprofloxacin Following Sensitivity testing: Piperacillin/tazobactamComplete recoveryEstrela and Abraham \[[@cit0077]\] *B. vancanneytii*2010N/AGermanyN/AEndocarditisN/AN/AN/AN/A[^2] Table 3.Incidences of *Brevundimonas* spp. infection from 2010 -- 2017. Main characteristics of the case reports.Author (Ref)YearSex/AgeCountryCo-morbidityType of infectionSusceptible toTResistance toAntibiotic treatmentOutcomeShang et al. \[[@cit0078]\], *B. vesicularis*2011M/83TaiwanType 2 diabetes, HypertensionProgressive leucocytosis/HAAmikacin, Ampicillin/Sulbactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Ertapenem, Gentamicin, Imipenem, Piperacillin/TazobactamAmpicillin, CiprofloxacinN/AComplete recoveryShang et al. \[[@cit0078]\], *B. vesicularis*2011M/25TaiwanLymphomaFebrile neutropenia/HAAmikacin, Ampicillin/Sulbactam, Cefazolin, Ceftriaxone, Ertapenem, Gentamicin, Imipenem, Piperacillin/TazobactamAmpicillin, Ceftazidime, Cefepime, CiprofloxacinCeftriaxoneComplete recoveryBhatawadekar & Sharma \[[@cit0079]\] *B. vesicularis*2011F/InfantIndiaInfantBacteraemia/CAAmikacin, Amoxicillin, Cefotaxime, Ciprofloxacin, Gentamicin, First Generation Cephalosporins, Imipenem, Meropenem, Piperacillin, TicarcillinCeftazidime, Cefoxitin, Co-trimaxazole,, NetilmicinCefotaximeComplete recoveryYoo et al. \[[@cit0080]\], *B. vesicularis*2012M/30South KoreaN/ALiver AbscessAmikacin, Ampicillin-Sulbactam, ImipenemAztreonam, Ceftazidime, Cefepime, CiprofloxacinCeftriaxone, Ampicillin-SulbactamComplete recoveryAlmuzara et al. \[[@cit0047]\], *B. diminuta*2012F/56ArgentinaLupus glomerulonephritisLeg ulcerMinocycline, TigecyclineAmpicillin, Ampicillin/Sulbactam, Aztreonam, Cefalotin, Cefoxitin, Cefotaxime, Ceftazidime, Cefepime, Ciprofloxacin, Colistin, Gentamicin, Imipenem, Meropenem, Piperacillin/Tazobactam, Trimethoprim- sulfamethoxazoleTigecycline plus imipenem.Complete recoveryKaradag et al. \[[@cit0081]\], *B. vesicularis*2012M/InfantTurkeyNeonateNeonatal sepsisAmikacin, Ceftriaxone, Gentamicin, ImipenemAmpicillin, third-generation Cephalosporins, piperacillin-tazobactamEmpirical Ampicillin, Gentamicin. After susceptibility testing Meropenem followed by ciprofloxacinComplete recoveryKhalifa  et al. \[[@cit0048]\], *B. vesicularis*2012F/InfantTunisiaPompe diseaseBacteraemiaAmikacin, Aztreonam Cefotaxime, Ceftazidime, Ciprofloxacin, Gentamicin, Imipenem, Ofloxacin, Piperacillin/ tazobactamPpiperacillin, TicarcillinCeftazidime 100 mg / kg daily for 10 days and Amikacin 15 mg / kg dailyComplete recoveryPandit et al. \[[@cit0082]\], *B. diminuta*2012F/66USAN/AKeratitis/CAAmikacin, Gentamicin, TobramycinAmpicillin, Cefotaxime, Ceftazidime, Ciprofloxacin, MoxifloxacinBesifloxacin and Tobramycin, Following identification Tobramycin was changed to GentamicinComplete recoveryLu et al. \[[@cit0045]\], *B. diminuta*2013M/38ChinaNonePleuritisAmikacin, Chloramphenicol, Gentamicin, Cefoperazone-Sulbactam, Meropenem, Piperacillin/tazobactam, TetracyclineAztreonam, Ceftazidime, Cefepime, Ciprofloxacin, Levofloxacin, Trimethoprim-sulfamethoxazoleInitially: Ciprofloxacin After Treatment failure: Piperacillin/tazobactamComplete recoveryNandy et al. \[[@cit0083]\], *B. vesicularis*2013F/InfantIndiaInfantBacteraemiaMeropenem, Ceftazidime/ Clavulanic acid, Netilimycin, Cefepime, Ampicillin/Sulbactam, Piperacillin/Tazobactam, Levofloxacin, Ciprofloxacin, Ceftazidime, Tobramycin, GentamicinCotrimaxazole, Nalidixic acidPiperacillin/ Tazobactam, Amikacin, Gentamycin, Fluconazole, Ciprofloxacin, MeropenemComplete recoveryShobha et al. \[[@cit0084]\], *B. diminuta*2013InfantIndia NoneUrinary Tract InfectionAmikacin, Amoxicillin-Clavulanic acid, Cefotaxime, Cefepime, Imipenem, Ticarcillin/clavunalic acid, Trimethoprim--sulfamethoxazoleAmpicillin, CiprofloxacinTicarcillin/clavulanic acidComplete recoveryGupta et al. \[[@cit0049]\], *B. vesicularis*2014M/24IndiaNoneUrinary Tract InfectionMinocycline, Piperacillin/tazobactam Trimethoprim--sulfamethoxazoleAmikacin, Amoxicillin, Amoxicillin-Clavulanate, Aztreonam Ceftazidime, Cefoperazone, Cefoperazone-Sulbactam, Cefoxitin, Cefotaxime, Colistin, Ertapenem, Gentamicin, Imipenem, Levofloxacin, Meropenem, Netilmicin, Norofloxacin, TobramycinAmikacin, Piperacillin/tazobactamComplete recoveryShujat et al. \[[@cit0085]\], *B. vesicularis*2014FPakistanGall Bladder issuesBacteraemiaN/AN/AMeropenemComplete recoveryKishore \[[@cit0086]\] *B. vesicularis*2014M/51IndiaDiabetes Mellitus (Type 2), Coronary Artery DiseaseBacteraemiaN/AAmpicillin-SulbactamAmikacin, AmoxyclavComplete recoveryMahapatra et al. \[[@cit0087]\], *B. diminuta*2014M/35IndiaN/APost traumatic abscessN/AN/AN/AComplete recoveryRa et al. \[[@cit0088]\], *B. vesicularis*2015F/71South KoreaEnd stage renal disease, Hypertension and diabetes mellitusperitoneal dialysis-associated peritonitisCefepime, Cefotaxime, Gentamicin, Imipenem, PiperacillinN/A1-g dose of Cefazolin and 1-g dose of Ceftazidime per dayComplete recovery following catheter removalCao et al. \[[@cit0089]\], *B. diminuta*2015M/62ChinaMyelodysplastic syndrome, Diabetes Mellitus (Type 2)BacteraemiaAmpicillin, Amikacin, Ceftriaxone, Cefepime, Cefazolin, Ceftazidime, Ciprofloxacin, Gentamicin, Imipenem, Levofloxacin, Piperacillin/tazobactam Trimethoprim--sulfamethoxazoleAztreonam, TobramycinN/AComplete recoverySingh and Bhatia \[[@cit0090]\] *B. vesicularis*20158 month oldIndiaInfantSepticaemia/ CAAmikacin, Cefoperazone, Levofloxacin, Piperacillin/tazobactamAmoxicillin-Clavulanate, CeftazidimeInitially: Amikacin, Ceftriaxone, Vancomycin Following Sensitivity testing: Cefoperazone, Levofloxacin,Complete recoveryChandra et al. \[[@cit0091]\], *B. vesicularis*2017M/18IndiaNephrotic syndromeNephrotic syndromeimipenem, meropenem, amikacin, gentamicin, fluoroquinolones, minocycline, tigecycline, cefoperazone-sulbactam, ceftazidime, cefepime, and cotrimoxazoleColistin cefoperazone-sulbactam 1.5 g iv BD for 2 weeksComplete recoverySwain and Rout \[[@cit0092]\] *B. diminuta*2017M/56IndiaType-2 diabetes mellitus, hypertension with epileptic disorderBacteraemiaAmikacin, Ceftazidime, Ceftazidime/clavulanic acid, Cefuroxime, Ceftriaxone, Ciprofloxacin, Levofloxacin, NetilimycinAmoxicillin/clavulanic acidAmikacin, CeftazidimeComplete recovery[^3] Table 4.Molecular methods applied to identify *Brevundimonas* spp. \[[@cit0045]\].MethodTargetSequenceSpeciesReal Time PCRgyrB Forward Primer*Brevundimonas diminuta*  ATCGAGATCATGCTGCACTATGAGGG   Reverse Primer   TGTTGTTGGTGAAGCACAGCATGG   Real-Time Probe   ACGTCATCGTCATTCGCGGCCAGAA Real Time PCR*rpoD* Forward Primer AGTTCCTCAAGGCCTATTTCGGCT*Brevundimonas diminuta*  Reverse Primer   GGCTTCATTCTCGCTGAACTTGGT   Real-Time Probe   AGCGCATCAAGGAGATGGGCGT FISHgyrB AAGAAGCACAGCGTCCGCTTCGAGC*Brevundimonas diminuta*FISH*rpoD* TCAAGGCCTATTTCGGCTCGGAGAT*Brevundimonas diminuta*

Co-Infection {#s0004-0002}
------------

Reports of cases of co-infection with *Brevundimonas* spp and other bacteria were rare with only two instances (one individual case and four cases as part of an outbreak) of co-infection being described in the literature. Han et al described seven cases of infection with *B. diminuta* within the same outbreak, four of these cases had other microorganism\'s co-isolated (coagulase-negative *Staphylococcus* -- bacteraemia, *Moraxella osloensis* -- catheter, *Enterococcus* sp. -- UTI and *Staphylococcus aureus* -- empyema) \[[@cit0046]\]. Gupta et al. found co-infection (in a UTI) of *B. vesicularis* along with *Candida tropiclis* and *Acinetobacter* spp. \[[@cit0049]\].

Pseudo-outbreaks {#s0004-0003}
----------------

As can be seen in [Table 5](#t0005){ref-type="table"} to date only two pseudo-outbreaks have been reported with *Brevundimonas* spp. Pseudo-outbreaks can be problematic as they can result in superfluous treatments given to patients (e.g. unnecessary antibiotics or the removal of indwelling devices such as catheters) and can waste valuable time and resources in the clinical setting. The causes of pseudo-outbreaks may be due to a number of different factors such as contaminated water used in the bacterial testing procedures or contamination of materials used in laboratory testing. Kim et al \[[@cit0050]\] described how *B. diminuta* was the cause of a pseudo-outbreak in a general hospital ward in South Korea. Patients did not display symptoms associated with bacterial infection, even though the organism was detected. The source of the *B. diminuta* contamination was not discovered. Lee *et al.* \[[@cit0051]\]. described *B. diminuta* as the cause of pseudo-outbreak in a tertiary care centre in the USA. The contamination was traced to pre-prepared inoculant media (used in the testing procedures for bacterial detection). Table 5.Incidences of *Brevundimonas* spp. Pseudo-infection from 1978 -- 2017. Main characteristics of the case reports.Author (Ref)YearSex/AgeCountryCo-morbidityType of infectionSusceptible toResistance toAntibiotic treatmentOutcomeKim et al. \[[@cit0050]\], *B. diminuta*2011Multiple (3 cases)South KoreaMultiplePseudobacteraemiaN/AAmikacin, Ciprofloxacin, Colistin, Ceftazidime, Cefepime, Cefotaxime Imipenem, Piperacillin / Tazobactam, TobramycinAmpicillin / sulbactam, Cefpiran, Metronidazole, NetilmicinN/ALee et al. \[[@cit0051]\], *B. diminuta*2017Multiple (12 cases)USAMultiplePesudo-infectionLevofloxain, Meropenem, Piperacillin/tazobactam, Trimethoprim--sulfamethoxazoleCeftazidimeN/AN/A[^4]

Treatment {#s0004-0004}
---------

The treatment of *Brevundimonas* spp. infections is frequently difficult, as these bacteria can be resistant to many different antibiotics including β-lactams and fluoroquinolones \[[@cit0046],[@cit0047]\]. There have been no controlled trials of antimicrobial therapy for *Brevundimonas* spp. infections in humans therefore therapy should be informed by the results of *in vitro* susceptibility testing on isolates. In the majority of cases listed in [Table 1--3](#t0001 t0002 t0003){ref-type="table"} cephalosporins, penicillins or aminoglycoside antibiotics were given to treat patients and these were mostly successful.

Little is known about resistance mechanisms in *Brevundimonas* spp. Resistance to the fluoroquinolone family of antibiotics has been detected in outbreaks due to mutations in the quinolone resistance-determining region (QRDR) of the host *gyrA*, gyrB and *parC* genes \[[@cit0046]\]. Bla~VIM-2~ and Bla~VIM-13~, which mediate resistance to almost all β-lactams (except aztreonam), have been found in both environmental and clinical isolates of *B. diminuta* \[[@cit0047]\]. The presence of *Bla*~VIM-2~ is related to a Tn*1721-*class 1 integron which was discovered in all *B. diminuta* isolates, with the determinant located on a plasmid \[[@cit0047]\]. This integron also had an *aac* (*6*′)-*Ib* gene, which mediates resistance to aminoglycoside antibiotics. Tetracycline resistance genes have also been found in environmental isolates of *B. diminuta* \[[@cit0052]\].

Breakdown of cases of infection with Brevundimonas spp. {#s0004-0005}
-------------------------------------------------------

Literature searches presented in [Table 1--3](#t0001 t0002 t0003){ref-type="table"} illustrate 49 separate instances of infection relating to *Brevundimonas* spp. The majority of these instances were infection with *B. vesicularis* (thirty-five cases -- 71%). One outbreak had both *B. vesicularis* and *B. diminuta* and one case of infection with *B. vancanneytii* was reported. The rest of the cases were made up *B. diminuta* infections (twelve cases- 24%). The major breakdown of condition were as follows: seventeen instances of bacteraemia (34%), five instances of septicaemia/sepsis (10%), three instances of pneumonia/ pleuritis (6%), two instances each endocarditis (4%), keratitis (4%), and urinary tract infection (4%). Serious infections with *Brevundimonas* spp include four instances of septicaemia (8%), two of endocarditis (4%), one of septic arthritis (2%) and one of meningitis (2%). Other conditions include instances of two cases of tonsillitis (2%), two of liver abscess (2%) and two of botryomycosis (2%). There have also been two reported instances (4%) of *Brevundimonas* spp infection that have caused two or more conditions: bacteraemia and reactive arthritis and bacteraemia, urinary tract infection and empyema. Four instances of death have been related to *Brevundimonas* spp infection, three of bacteraemia and one of septicaemia.

Conclusions {#s0004-0006}
-----------

*Brevundimonas* spp. are not currently considered as major pathogens. However, this should be re-evaluated in light of our investigations where forty-nine examples of *Brevundimonas* spp. infections have been found in the literature. These species have characteristics, such as ability to pass through sterilising filters, which may allow them to cause potentially harmful infections and even death on occasion. Although it is of low virulence and not as big a risk as other non-fermenting Gram-negative bacteria such as *Burkholderia* etc., it should not be over looked as a possible cause of nosocomial infections and should be considered for inclusion in hospital screening and prevention programs. These programs should consider investigation of possible *Brevundimonas* spp outbreaks if these bacteria are clinically isolated in more than one patient.

[^1]: M- Male, F- Female, N/A -- Not Available, CA -- Community Acquired, HA- Hospital Acquired.

[^2]: M- Male, F- Female, N/A -- Not Available, CA -- Community Acquired, HA- Hospital Acquired.

[^3]: M- Male, F- Female, N/A -- Not Available, CA -- Community Acquired, HA- Hospital Acquired.

[^4]: M- Male, F- Female, N/A -- Not Available
